AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Presentation (July 2004)
17 slides from AstraZeneca's investor presentation, July 2004
Slide 1: General Presentation: HY 2004 Headline results
General Presentation July 2004 HY 2004 Headline results HY 04 HY 03 CER $m $m growth Sales 10,362 9,171 +5% Operating profit 2,190 2,161 -5% EPS $0.97 $0.93 -3% Share repurchase 968 311 2 1
Slide 2: 2Q 2004 Headline results; AstraZeneca strategy
2Q 2004 Headline results Q2 04 Q2 03 CER $m $m growth Sales 5,288 4,436 +11% Operating profit 1,111 889 +15% EPS $0.50 $0.39 +18% Share repurchase 360 182 3 AstraZeneca strategy 1999 2004 2008+ Deliver Top-tier financial performance Full potenti al of growth portfolio Driv e Produc tivity for c ompe
Slide 3: 2004 priorities; Crestor
2004 priorities Continue to build Crestor® into megabrand Drive Oncology portfolio Progress to US market leadership for Nexium® and Seroquel® First launches for Exanta® and register chronic claims Ad vance development projects Continuous improvement in productivity 2004 EPS range in range of $2. 00
Slide 4: Crestor: STELLAR study
Crestor®: STELLAR study LDL-C lowering across the dose range LDL-C: LS mean change from baseline at week 6 " " # $% & %% ### !!! !!! & %% ### ### ### !!! ' & %% ### ### ### ! "!# $ " %& " ' ()*+ , - 7 Reporting rates of rhabdomyolysis with statin therapy 0" 7 '." . " # ' '." #.8 9! :' : /04 " 2 5 '
Slide 5: Reporting rates of fatal rhabdomyolysis with statin therapy
Reporting rates of fatal rhabdomyolysis with statin therapy 0" 7 '." . " # ' '." # '.8 9! :' : /04 " 2 5 ' !6 !"4 " 3 + & %% !6 !" 22 *+& % % +& %% 3 $% & % % ' . "%" , & %% 3 + 5 ' & %% /0%" 1 . "%" & %% 3 % %% .%" 1 % %% -. & %% 3+ ." +& % % 3 ." 4. 0 "()) )()) "( )( "( )( "( )( (" ( " ()) ( ( ( (
Slide 6: Crestor: early launch markets; Oncology - progress
Crestor®: early launch markets < / ) < .;> =" 08 "2 )/ " < -< / < "/ " "/ 0 < < < 6= 6= 6= 6=( 6= 6=+ 6=- 4 ! "8"' ! /? /0 1" Sourc e: AZ CRESTOR Launchtrak Sys tem Data dis play ed in s hare of total pres criptions & tablets dis pens ed 11 Mark et = Selec ted C10A1/USC 32110 Dispens ed data Oncolog
Slide 7: Arimidex – strong growth continues
Arimidex® – strong growth continues 70000 Generics introduced 60000 in US ITA 50000 A ATAC 2nd Arimidex 40000 analysis Letrozole /0@ US Approval tamoxifen 30000 MA17 Exemestane 20000 IES Fadrozole 10000 0 Mar-02 Nov-03 Feb-04 Apr-02 May-02 Jun-02 Aug-02 Nov-02 Jan-03 Feb-03 Mar-03 Apr-03 May-03 Jul-
Slide 8: Novels continue to transform oncology market; Iressa
Novels continue to transform oncology market Novels account for 20% of market New ‘science’ delivering and gro wing 20 Improved molecular biology 18 16 understanding 14 12 $Bn 10 Novels transforming 8 oncology market 6 4 2 AZ - Leading pipeline 0 Q1/99 Q1/00 Q1/01 Q1/02 Q1/97 Q1/98 Q1/03 Q1/04 Cytot
Slide 9: US EAP 21,000 Patient Analysis: One Year Survival
US EAP 21,000 Patient Analysis: One Year Survival 30% 1.0 Median 1-year At risk (months) survival (%) 21,064 5.3 (95% CI 5.1-5.5) 29.9 (95% CI 28.8-31.1) 0.8 ~ 30% survival at 1 year Proportion event-free Massa relli et al 3r d & 4th line 0.6 Refer ence data Iressa® IDEAL 1 Iressa® IDEAL 2 Iressa® E
Slide 10: Iressa US 'uplift' post mutation data and ASCO; Seroquel
Iressa® US ‘uplift’ post mutation data and ASCO US Prescription trends (TRx / NRx) 10,000 9,000 8,000 7,000 6,000 Rx 5,000 4,000 3,000 2,000 1,000 0 Oct-03 Jun-03 Jul-03 Nov-03 Jan-04 Feb-04 Apr-04 May-04 Aug-03 Sep-03 Dec-03 Mar-04 Jun-04 Monthly Ne w Scripts Monthly Total Scripts Sourc e: IMS NPA
Slide 11: US: Trends in Antipsychotics with Seroquel
Rxs (Millions) M AT M 0 5 10 15 25 30 35 40 45 50 M ay AT -99 M Ju AT l- 9 9 M Se 45% 20 55% AT p- 9 9 M N ov AT -99 M J an Sourc e: IMS Health, NPA ; NSP AT 0- M Ma 0 AT r-0 M 0 M ay AT -00 M Ju AT l- 0 M Se 0 TYPICAL Rxs AT p- ATYPICAL Rxs 00 M N ov Schizophrenia AT -0 0 TYPICAL Sales ($m) M J an
Slide 12: Europe: Strong RX growth for atypicals
Europe: Strong RX growth for atypicals 1998 – Q1 2004 : Major Opportunity 45 TYPICAL Rxs $3,000 ATYPICAL Rxs 40 TYPICAL Sales ($m) ATYPICAL Sales ($m) $2,500 35 Sales (Millions USD) 30 $2,000 Rxs (Millions) 25 62% 80% $1,500 85% 20 15 $1,000 38% 10 20% $500 5 15% 0 $0 MAT MAT MAT MAT MAT MAT MAT MAT
Slide 13: Seroquel Bipolar Mania
Seroquel® Bipolar Mania Change from baseline (YMRS) 0 * p<0.05 ** p<0.01 *** p<0.001 -5 * ** -10 Placebo *** -15 *** *** *** Seroquel® *** *** -20 *** -25 4 7 14 21 28 42 56 70 84 Day YMRS – Young mania rating s c ale Sac hs et al Bipolar Dis orders 2004: 6: 213 25 Successful mania launch in Europe
Slide 14: Seroquel Bipolar Depression; Symbicort value share Europe
Seroquel® Bipolar Depression Study Week 0 1 2 3 4 5 6 7 8 0 Mean Change From Bas eline (MADRS) Quetiapi ne 60 0 mg (n=170) Quetiapi ne 30 0 mg (n=172) -5 Placeb o (n=169) * -10 * * * * * * -15 * * * * * * * * * -20 MAD R S, Mo n tg o me r y - As b er g D ep r es s io n Ra tin g Sc a le *P<0.001 (vs
Slide 15: Nexium US TRx PPI market share
Nexium® US TRx PPI market share 60% T otal Prescription Market Share (PPI) 50% 40% 30% 20% 10% 0% 0 0 00 01 01 02 02 3 3 3 04 4 0 1 1 2 02 3 -0 -0 -0 -0 l- 0 -0 -0 -0 -0 -0 -0 l- l- l- n- n- n- n n ct ct ct pr pr pr ct- pr pr Ju Ju Ju Ja Ja Ju Ja Ja Ja O O O A A A A A O Prilosec ® Nexium ® Prevacid®
Slide 16: US PPI market TRx growth; Exanta - regulatory status
US PPI market - TRx extended unit growth trends* Q103 Q203 Q303 Q403 Q104 Q204 June 90% 76% 70% TRx EU Gr owth % 56% 50% 47% 33% 31% 30% 26% 26% 22% 21% 16% 16% 18% 15% 15% 14% 9% 12% 10% 3% 0% -0.5% -10% -5% -3% -8% -12% -30% -34% -40% -42% -40% -50% PPI Omeprazole PPI ex-omep Nexium® *TR x EU g r
Slide 17: 2004 guidance – Q2 update
2004 guidance – Q2 update Strong second half earnings growth anticipated • Continued performance of growth portfolio • Slower growth of R&D and SG&A costs • Strong focus on productivity across the business Some reversal of YTD currency benefits expected Market trends may mitigate outcome Full year t